Related Experiment Video
Updated: Mar 19, 2026
Tracking the Mammary Architectural Features and Detecting Breast Cancer with Magnetic Resonance Diffusion Tensor Imaging
Published on: December 15, 2014
Early Detection of Treatment-Induced Mitotic Arrest Using Temporal Diffusion Magnetic Resonance Spectroscopy
Xiaoyu Jiang1, Hua Li1, Ping Zhao1
1Institute of Imaging Science, Vanderbilt University, Nashville, TN 37232, USA; Department of Radiology, Vanderbilt University, Nashville, TN 37232, USA; Department of Radiological Sciences, Vanderbilt University, Nashville, TN 37232, USA.
Purpose:
A novel quantitative magnetic resonance imaging (MRI) method, namely, temporal diffusion spectroscopy (TDS), was used to detect the response of tumor cells (notably, mitotic arrest) to a specific antimitotic treatment (Nab-paclitaxel) in culture and human ovarian xenografts and evaluated as an early imaging biomarker of tumor responsiveness.
Methods:
TDS measures a series of apparent diffusion coefficients (ADCs) of tissue water over a range of effective diffusion times, which may correspond to diffusion distances ranging from subcellular to cellular levels (~3-20 μm). By fitting the measured ADC data to a tissue model, parameters reflecting structural properties such as restriction size in solid tumors can be extracted. Two types of human ovarian cell lines (OVCAR-8 as a responder to Nab-paclitaxel and NCI/ADR-RES as a resistant type) were treated with either vehicle (PBS) or Nab-paclitaxel, and treatment responses of both in vitro and in vivo cases were investigated using TDS.
Results:
Acute cell size increases induced by Nab-paclitaxel in responding tumors were confirmed by flow cytometry and light microscopy in cell culture. Nab-paclitaxel-induced mitotic arrest in treated tumors/cells was quantified histologically by measuring the mitotic index in vivo using a mitosis-specific marker (anti-phosphohistone H3). Changes in the fitted restriction size, one of the parameters obtained from TDS, were able to detect and quantify increases in tumor cell sizes. All the MR results had a high degree of consistency with other flow, microscopy, and histological data. Moreover, with an appropriate analysis, the Nab-paclitaxel-responsive tumors in vivo could be easily distinguished from all the other vehicle-treated and Nab-paclitaxel-resistant tumors.
Conclusion:
TDS detects increases in cell sizes associated with antimitotic-therapy-induced mitotic arrest in solid tumors in vivo which occur before changes in tissue cellularity or conventional diffusion MRI metrics. By quantifying changes in cell size, TDS has the potential to improve the specificity of MRI methods in the evaluation of therapeutic response and enable a mechanistic understanding of therapy-induced changes in tumors.
Insights
Temporal diffusion spectroscopy (TDS) detects early cell size increases in tumors responding to antimitotic treatment, offering a new imaging biomarker for therapeutic response. This method quantizes cell size changes before conventional MRI metrics shift.
Area of Science:
- Oncology
- Radiology
- Biophysics
Background:
- Assessing early tumor response to antimitotic therapy is crucial for effective treatment selection.
- Conventional imaging biomarkers often lack the sensitivity to detect early treatment-induced changes.
- Novel quantitative MRI techniques are needed to provide earlier and more specific indicators of therapeutic efficacy.
Purpose of the Study:
- To evaluate temporal diffusion spectroscopy (TDS) as an early imaging biomarker for detecting tumor cell response to antimitotic treatment (Nab-paclitaxel).
- To investigate the ability of TDS to detect and quantify changes in tumor cell size associated with mitotic arrest.
- To compare TDS findings with conventional histological and microscopy data in vitro and in vivo.
Main Methods:
- Temporal diffusion spectroscopy (TDS) was employed to measure apparent diffusion coefficients (ADCs) over various diffusion times.
- Human ovarian cancer cell lines (responder and resistant) were treated with Nab-paclitaxel or vehicle, both in vitro and in vivo xenografts.
- TDS data were fitted to a tissue model to extract parameters like restriction size, reflecting cellular structural properties.
Main Results:
- TDS successfully detected acute cell size increases in Nab-paclitaxel-responding tumors, consistent with flow cytometry and microscopy.
- Quantified changes in fitted restriction size using TDS correlated with Nab-paclitaxel-induced mitotic arrest, confirmed by histological analysis (anti-phosphohistone H3).
- Nab-paclitaxel-responsive tumors were clearly distinguished from vehicle-treated and resistant tumors using TDS analysis.
Conclusions:
- Temporal diffusion spectroscopy (TDS) can detect cell size increases linked to antimitotic therapy-induced mitotic arrest in solid tumors.
- TDS quantifies cell size changes earlier than conventional diffusion MRI metrics or changes in cellularity.
- TDS holds potential for enhancing MRI specificity in evaluating therapeutic response and understanding treatment-induced tumor changes.
